Impact of humanised isolation and culture conditions on stemness and osteogenic potential of bone marrow derived mesenchymal stromal cells

被引:10
|
作者
Suliman, Salwa [1 ]
Ali, Hassan R. W. [1 ]
Karlsen, Tommy A. [2 ]
Amiaud, Jerome [3 ]
Mohamed-Ahmed, Samih [1 ]
Layrolle, Pierre [3 ]
Costea, Daniela E. [4 ,5 ,6 ]
Brinchmann, Jan E. [2 ,7 ]
Mustafa, Kamal [1 ]
机构
[1] Univ Bergen, Ctr Clin Dent Res, Dept Clin Dent, Bergen, Norway
[2] Oslo Univ Hosp, Dept Immunol, Norwegian Ctr Stem Cell Res, Rikshosp, Oslo, Norway
[3] Univ Nantes, Fac Med, Lab Bone Sarcomas & Remodeling Calcified Tissues, INSERM,UMR 1238,PHY OS, Nantes, France
[4] Univ Bergen, Dept Clin Med, Gade Lab Pathol, Bergen, Norway
[5] Haukeland Hosp, Dept Pathol, Bergen, Norway
[6] Univ Bergen, Ctr Canc Biomarkers, Bergen, Norway
[7] Univ Oslo, Fac Med, Dept Mol Med, Oslo, Norway
基金
欧盟地平线“2020”;
关键词
FETAL BOVINE SERUM; HUMAN PLATELET LYSATE; IN-VITRO EXPANSION; GENE-EXPRESSION; GROWTH-FACTOR; ADIPOSE-TISSUE; DIFFERENTIATION; PROLIFERATION; SUBSTITUTE; CRYOPRESERVATION;
D O I
10.1038/s41598-019-52442-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Therapeutic potential of human bone marrow stromal/stem cells (hBMSC) must be developed using well defined xenogenic-free conditions. hBMSC were isolated from healthy donors (n = 3) using different isolation and expansion methods. Donor I was isolated and expanded by either bone marrow directly seeded and cells expanded in 10% AB human serum (AB) + 5 ng/ml fibroblast growth factor-2 (FGF2) [Direct(AB + FGF(low))] or Ammonium-Chloride-Potassium Lysing Buffer was used before the cells were expanded in 10% AB + 5 ng/ml FGF-2 [ACK(AB + FGF(low))] or Lymphoprep density gradient medium was used before the cells were expanded in 10% AB + 5 ng/ml FGF2 [Lympho(AB + FGF(low))] or bone marrow directly seeded and cells expanded in 10% pooled platelet lysate plasma (PL) + heparin (2 I/U/mL) [Direct(PL)]. Groups for donors II and III were: Direct(AB + FGF(low)) or 10% AB + 10 ng/ml FGF2 [Direct(AB + FGF(high))] or Direct(PL). HBMSCs were assessed for viability, multi-potency, osteogenic, inflammatory response and replicative senescence in vitro after 1 and 3 weeks. Pre-selected culture conditions, Direct(AB + FGF(high)) or Direct(PL), were seeded on biphasic calcium phosphate granules and subcutaneously implanted in NOD/SCID mice. After 1 and 11 weeks, explants were analysed for inflammatory and osteogenic response at gene level and histologically. To identify implanted human cells, in situ hybridisation was performed. hBMSC from all conditions showed in vitro multi-lineage potency. hBMSCs expanded in PL expressed stemness markers in vitro at significantly higher levels. Generally, cells expanded in AB + FGF2 conditions expressed higher osteogenic markers after 1 week both in vitro and in vivo. After 11 weeks in vivo, Direct(AB + FGF(high)) formed mature ectopic bone, compared to immature mineralised tissues formed by Direct(PL) implants. Mouse responses showed a significant upregulation of IL-1 alpha and IL-1 beta expression in Direct(PL). After 1 week, human cells were observed in both groups and after 11 weeks in Direct(AB + FGF(high)) only. To conclude, results showed a significant effect of the isolation methods and demonstrated a relatively consistent pattern of efficacy from all donors. A tendency of hBMSC expanded in PL to retain a more stem-like phenotype elucidates their delayed differentiation and different inflammatory expressions.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Enhancing the osteogenic potential of bone-marrow derived progenitor cells in primary culture.
    Goltry, K. L.
    Lee, J. J.
    Parrish, C. R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S391 - S391
  • [42] Mitophagy promotes the stemness of bone marrow-derived mesenchymal stem cells
    Feng, Xiaorong
    Yin, Wen
    Wang, Jialing
    Feng, Li
    Kang, Y. James
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2021, 246 (01) : 97 - 105
  • [43] Age-related decrease in the osteogenic potential of human bone marrow mesenchymal stromal stem cells.
    DIppolito, G
    Schiller, PC
    Ricordi, C
    Howard, GA
    Roos, BA
    JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : S216 - S216
  • [44] Osteogenic differentiation and angiogenesis with cocultured adipose-derived stromal cells and bone marrow stromal cells
    Kim, Kyung-Il
    Park, Siyeon
    Im, Gun-Il
    BIOMATERIALS, 2014, 35 (17) : 4792 - 4804
  • [45] Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow
    D'Ippolito, G
    Schiller, PC
    Ricordi, C
    Roos, BA
    Howard, GA
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (07) : 1115 - 1122
  • [46] Isolation, selection and culture methods to enhance clonogenicity of mouse bone marrow derived mesenchymal stromal cell precursors
    Claas Baustian
    Shirley Hanley
    Rhodri Ceredig
    Stem Cell Research & Therapy, 6
  • [47] Isolation, selection and culture methods to enhance clonogenicity of mouse bone marrow derived mesenchymal stromal cell precursors
    Baustian, Claas
    Hanley, Shirley
    Ceredig, Rhodri
    STEM CELL RESEARCH & THERAPY, 2015, 6
  • [48] Simple Isolation of Human Bone Marrow Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells
    Tonyali, Guelsena
    Kilic, Emine
    Muratoglu, Bihter
    Alpdundar-Bulut, Esin
    Ozdemir, Cansu
    Uckan-cetinkaya, Duygu
    CURRENT PROTOCOLS, 2025, 5 (01):
  • [49] Inhibition of osteogenic and adipogenic potential in bone marrow-derived mesenchymal stem cells under osteoporosis
    Huang, Tingben
    Yu, Zhou
    Yu, Qiong
    Wang, Ying
    Jiang, Zhiwei
    Wang, Huiming
    Yang, Guoli
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 525 (04) : 902 - 908
  • [50] Uremic Serum Impairs Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stromal Cells
    Della Bella, Elena
    Pagani, Stefania
    Giavaresi, Gianluca
    Capelli, Irene
    Comai, Giorgia
    Donadei, Chiara
    Cappuccilli, Maria
    La Manna, Gaetano
    Fini, Milena
    JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (08) : 2201 - 2209